drugset / Trial / NCT00835484
Cefdinir Capsules 300 mg, Fasting
RandomizedCrossoverOpen-labelOther
Summary
This study will compare the relative bioavailability (rate and extent of absorption) of 300 mg Cefdinir Capsules manufactured and distributed by TEVA pharmaceuticals USA with that of OMNICEF® Capsules by CEPH International Corporation for Abbott Laboratories following a single oral dose (1 x 300mg capsule) in healthy adult subjects administered under fasting conditions.
Timeline
- Start
- 2005-07
- Primary completion
- 2005-07
- Completion
- 2005-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | cefdinir | Other / unclassified | 300 mg | Oral |
Indications
No indication recorded.